a public good project by the
Synthesis
Company
of California

© 2026

Minish Jain | doi.page

0 works0 citations0 h-index

Minish Jain

George Washington University(US)Veterans Health Administration(US)Ruby Hall Clinic(IN)University of California System(US)Washington DC VA Medical Center(US)

Publications by Year

Research Areas

Prostate Cancer Treatment and Research, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses

Most-Cited Works

→ A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer(2015)267 cited
→ A Randomized Phase 2 Study of ADXS11-001 Listeria monocy'togenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer(2018)171 cited
→ Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial(2015)131 cited
→ Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study(2015)102 cited
→ Complications of Allogeneic Hematopoietic Stem Cell Transplantation(2014)87 cited
→

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

(2012)

85 cited

→ The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer:(2011)59 cited

→ Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study(2016)55 cited

→ Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care(2014)43 cited

→ A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).(2009)37 cited